{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:09:36Z","timestamp":1790266176249,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmorw.2026.100724","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:39:54Z","timestamp":1781545194000},"page":"100724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Retrospective analysis of real-world clinical use of comprehensive genomic profiling in solid tumors in Finland 2017-2020"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7217-9711","authenticated-orcid":false,"given":"M.","family":"Myllynen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kononen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1925-0192","authenticated-orcid":false,"given":"E.","family":"Alanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Koivunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Anttalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-361X","authenticated-orcid":false,"given":"L.","family":"Ukkola-Vuoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1879-0739","authenticated-orcid":false,"given":"S.","family":"Tuominen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"M\u00e4kinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.esmorw.2026.100724_bib1","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100724_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100724_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/17407745231182013","article-title":"The Targeted Agent and Profiling Utilization Registry Study: a pragmatic clinical trial","volume":"20","author":"Mangat","year":"2023","journal-title":"Clin Trials"},{"issue":"7776","key":"10.1016\/j.esmorw.2026.100724_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100724_bib5","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3390\/cancers15071967","article-title":"Precision oncology: evolving clinical trials across tumor types","volume":"15","author":"Song","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmorw.2026.100724_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102721","article-title":"If it\u2019s a target, it\u2019s a pan-cancer target: tissue is not the issue","volume":"125","author":"Adashek","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.esmorw.2026.100724_bib7","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100724_bib8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100724_bib9","first-page":"264","article-title":"Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance","volume":"74","author":"Casolino","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100724_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/jpm12010072","article-title":"Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe","volume":"12","author":"Horgan","year":"2022","journal-title":"J Pers Med"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100724_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105810","article-title":"Access to novel cancer medicines in Europe: inequities across countries and their drivers","volume":"10","author":"Hofmarcher","year":"2025","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100724_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291495","article-title":"Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)","volume":"18","author":"Leroy","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100724_bib13","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00432-022-04165-0","article-title":"Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board","volume":"149","author":"Heinrich","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100724_bib14","article-title":"Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care","volume":"11","author":"Sellmann","year":"2026","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.esmorw.2026.100724_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/1651-226X.2026.44889","article-title":"Procedures of data merging in precision cancer medicine: the PRIME-ROSE project","volume":"65","author":"Van der Pol","year":"2026","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmorw.2026.100724_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/1651-226X.2024.32661","article-title":"A national precision cancer medicine implementation initiative for Finland","volume":"63","author":"Jalkanen","year":"2024","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100724_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00ae CDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100724_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.esmorw.2026.100724_bib19","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100724_bib20","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.esmorw.2026.100724_bib21","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100724_bib22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.annonc.2025.04.004","article-title":"Copenhagen Prospective Personalized Oncology (CoPPO)-impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting","volume":"36","author":"Belcaid","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmorw.2026.100724_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100832","article-title":"Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis","volume":"32","author":"Talvitie","year":"2022","journal-title":"Neoplasia"},{"issue":"19","key":"10.1016\/j.esmorw.2026.100724_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71250","article-title":"Comprehensive genomic profiling in advanced non-small cell lung cancer: a real-world cohort study in Finland","volume":"14","author":"Hormalainen","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmorw.2026.100724_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100724_bib26","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1535-7163.MCT-14-1061","article-title":"On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients","volume":"14","author":"Schwaederle","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100724_bib27","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100724_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266112","article-title":"Clinical utility of comprehensive genomic profiling in Japan: result of PROFILE-F study","volume":"17","author":"Aoyagi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.esmorw.2026.100724_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2340\/1651-226X.2024.28322","article-title":"IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results","volume":"63","author":"Puco","year":"2024","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmorw.2026.100724_bib30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2340\/1651-226X.2025.43366","article-title":"Feasibility and outcome of genomics-guided treatment selection in advanced cancer \u2013 the MEGALiT explorative clinical trial","volume":"64","author":"Ny","year":"2025","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100724_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.36741","article-title":"Comparison of solid tumor treatment response observed in clinical practice with response reported in clinical trials","volume":"4","author":"Feinberg","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100724_bib32","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1158\/1078-0432.CCR-18-1780","article-title":"Copenhagen Prospective Personalized Oncology (CoPPO)-clinical utility of using molecular profiling to select patients to phase I trials","volume":"25","author":"Tuxen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmorw.2026.100724_bib33","doi-asserted-by":"crossref","first-page":"S607","DOI":"10.1016\/j.annonc.2025.08.1558","article-title":"989P Efficacy of molecularly matched, targeted therapies outside current drug indications: results from the first 301 patients treated in the ProTarget trial","volume":"36","author":"Kringelbach","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmorw.2026.100724_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.089","article-title":"81P FINPROVE: the Finnish national study to facilitate patient access to targeted anti-cancer drugs \u2013 preliminary data after two years of enrollment","volume":"35","author":"Jalkanen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmorw.2026.100724_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2245","article-title":"LBA7 The Rome trial from histology to target: the road to personalize targeted therapy and immunotherapy","volume":"35","author":"Botticelli","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100724_bib36","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41591-025-03918-x","article-title":"Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial","volume":"31","author":"Marchetti","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100724_bib37","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100724_bib38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.esmorw.2026.100724_bib39","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1002\/cam4.4076","article-title":"Clinical and cost outcomes following genomics-informed treatment for advanced cancers","volume":"10","author":"Weymann","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100724_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12885-023-10632-9","article-title":"ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling \u2013 a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial","volume":"23","author":"Kringelbach","year":"2023","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.esmorw.2026.100724_bib41","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(24)00286-9","article-title":"Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis","volume":"25","author":"Jenei","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmorw.2026.100724_bib42","article-title":"An approach to solving the complex clinicogenomic data landscape in precision oncology: learnings from the design of WAYFIND-R, a global precision oncology registry","volume":"6","author":"Le Tourneau","year":"2022","journal-title":"JCO Precis Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:41:52Z","timestamp":1790264512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S2949820126000433"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100724","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective analysis of real-world clinical use of comprehensive genomic profiling in solid tumors in Finland 2017-2020","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100724"}}